[1]全国第五次结核病流行病学抽样调查技术指导组,全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告.中国防痨杂志,2012,34(8):485-508.[2]Wirth T, Hildebrand F, Allix-Béguec C, et al.Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog,2008,4(9):e1000160.[3]Motiwala AS, Dai Y, Jones-López EC,et al. Mutations in extensively drug-resistant Mycobacterium tuberculosis that do not code for known drug-resistance mechanisms.J Infect Dis,2010,201(6):881-888.[4]Marttila HJ,Soini H,Eerola E,et al.A Ser315 Thr substitution in katG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St.Petersburg area in Russia.Antimicrob Agents Chemother,1998,42(9):2443-2445.[5]Coll P, Aragón LM, Alcaide F,et al.Molecular analysis of isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates recovered from Barcelona. Microb Drug Resist,2005,11(2):107-114.[6]Haas WH, Schilke K, Brand J, et al. Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa.Antimicrob Agents Chemother,1997,41(7):1601-1603.[7]Musser JM, Kapur V, Williams DL, et al. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance.J Infect Dis,1996,173(1):196-202.[8]Rouse DA,Morris SL. Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis.Infect Immun,1995,63(4):1427-1433.[9]Lee AS, Tang LL, Lim IH,et al.Lack of clinical significance for the common arginine-to-leucine substitution at codon 463 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis in Singapore.J Infect Dis,1997,176(4):1125-1126.[10]Cockerill FR 3rd, Uhl JR, Temesgen Z, et a1.Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase(KatG)gene associated with isoniazid resistance.J Infect Dis,1995,171(1):240-245.[11]Banerjee A, Dubnau E, Quemard A,et al.inhA,a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science,1994,263(5144):227-230.[12]Dessen A, Quémard A, Blanchard JS, et al. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science,1995,267(5204):163-1641.[13]Rozwarski DA, Grant GA, Barton DH, et al.Modification of the NADH of the isoniazid target(inhA)from Mycobacterium tuberculosis. Science,1998,279(5347):98-102.[14]Zhang Y,Young D. Molecular genetics of drug resistance in Mycobacterium tuberculosis.J Antimicrob Chemother,1994,34(3):313-319.[15]Morlock GP,Metchock B,Sikes D,et al.ethA,inhA,and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother, 2003, 47(12): 3799-3805.[16]Ano H,Matsumoto T,Nangi T,et al.Resistance-conferring mutations of Mycobacterium tuberculosis strains with low level resistance to isoniazid. Kekkaku,2006,81(12):709-713.[17]Guo H,Seet Q,Denkin S,et al. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA.J Med Microbiol, 2006,55(Pt 11):1527-1531.[18]Larsen MH, Vilchèze C, Kremer L, et al.Overexpression of inhA,but not kasA,confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M.Bovis BCG and M.tuberculosis. Mol Microbiol,2002,46(2):453-466.[19]Lee AS,Lim IH,Tang LL,et al.Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore.Antimicrob Agents Chemother,1999,43(8):2087-2089.[20]Piatek AS,Telenti A,Murray MR,et al.Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons:implications for rapid susceptibility testing.Antimicrob Agents Chemother,2000,44(1):103-110.[21]Lee AS, Teo AS, Wong SY.Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates.Antimicrob Agents Chemother,2001,45(7):2157-2159.[22]Enne VI,Delsol AA,Roe JM,et al.Rifampicin resistance and its fitness cost in Enterococcus faecium. J Antimicrob Chemother,2004,53(2):203-207.[23]Lee JH,Ammerman NC,Nolan S,et al.Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis.Nat Commun,2012,3(753):1-8.[24]Viader-Salvadó JM, Luna-Aguirre CM, Reyes-Ruiz JM,et al.Frequency of mutations in ropB and codons 315 and 463 of katG in rifampin- and/or isoniazid-resistant Mycobacterium tuberculosis isolates from northeast Mexico.Microb Drug Resist,2003,9(1):33-38.[25]Mokrousov I,Narvskaya O,Otten T,et al.High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from morthwestern Russia,1996 to 2001.Antimicrob Agents Chemother, 2002, 46(5):1417-1424.[26]熊札宽.结核病实验诊断学.北京:人民卫生出版社,2008:54-68.[27]Moghazeh SL,Pan X,Arain T,et al.Comparative antimycobacterial activities of riampin,rifapentine,and KRM-1648 against a collection of rifamin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother,1996,40(11):2655-2657.[28]Ohno H,Koga H,Kohno S,et al.Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother,1996,40(4):1053-1056.[29]徐瑛.耐多药结核病研究进展.预防医学情报杂志,2008,24(4):290-292.[30]Zhang Y,Mitchison D. The curious characteristics of pyrazinamide: a review.Int J Tuberc Lung Dis,2003,7(1):6-21.[31]Unissa AN,Selvakumar N,Hassen S.Insight to pyrazinamide resistance in Mycobacterium tuberculosis by molecular docking. Bioinformation,2009,4(1):24-29.[32]Petrella S,Gelus-Ziental N,Maudry A,et al.Crystal structrure of the pyrazinamidase of Mycobacterium tuberculosis:insights into natural and acquired resistance to pyrazinamide.PLoS One,2011,6(1):1-8.[33]洪创跃,刘小立,桂静,等.耐多药结核分枝杆菌pncA基因突变特征及与吡嗪酰胺耐药相关性研究.中华预防医学杂志,2012,46(5):436-439.[34]Cuevas-Córdoba B, Xochihua-González SO, Cuellar A, et al. Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico.Infect Genet Evol,2013, pii: S1567-1348(12)00395-4.[35]Shi W,Zhang X,Jiang X,et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.Science,2011,333(6049):1630-1632.[36]Mokrousov I,Otten T,Vyshnevskiy B,et al. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from Northwestern Russia: implications for genotypic resistance testing.J Clin Microbiol,2002,40(10):3810-3813.[37]Ramaswamy SV, Amin AG, Gksel S, et al.Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis.Antimicrob Agents Chemother,2000,44(2):326-336.[38]Dobner P, Bretzel G, Rüsch-Gerdes S, et al.Geographic variation of the predictive values of genomic mutations associated with streptomycin resistance in Mycobacterium tuberculosis.Mol Cell Probes,1997,11(2):123-126.[39]Okamoto S, Tamaru A, Nakajima C, et al. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol Microbiol,2007,63(4):1096-1106.[40]Maus CE,Plikaytis BB,Shinnick TM.Molecular analysis of cross-resistance to capreomycin,kanamycin,amikacin,and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother,2005,49(8):3192-3197.[41]Zaunbrecher MA,Sikes RD Jr,Metchock B,et al.Over expression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A,2009,106(47):20004-20009.[42]刘雪梅,谢建平.卷曲霉素作用机制和耐药机制的功能基因组学研究进展.药学学报,2008,43(8):788-792.[43]Giannoni F,Iona E,Sementilli F,et al.Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis.Antimicrob Agents Chemother,2005,49(7):2928-2933.[44]李国利,陈澎,孙昌文,等.结核分枝杆菌对左氧氟沙星与莫西沙星的交叉耐药性及gyrA和gyrB基因突变分析.中国防痨杂志,2010,32(10):616-621.[45]Hegde SS, Vetting MW, Roderick SL, et al, A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science,2005,308(5727):1480-1483.[46]Buriánková K, Doucet-Populaire F, Dorson O, et al. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother,2004,48(1):143-150.[47]Hillemann D, Rüsch-Gerdes S, Richter E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother, 2008,52(2):800-801. |